As of 2025-09-17, the EV/EBITDA ratio of Y-mAbs Therapeutics, Inc (YMAB) is -15.86. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. YMAB's latest enterprise value is 328.95 mil USD. YMAB's TTM EBITDA according to its financial statements is -20.75 mil USD. Dividing these 2 quantities gives us the above YMAB EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.3x - 17.2x | 15.6x |
| Forward P/E multiples | 22.4x - 34.3x | 27.4x |
| Fair Price | (8.87) - (6.49) | (8.45) |
| Upside | -203.0% - -175.4% | -198.1% |
| Date | EV/EBITDA |
| 2025-09-15 | -15.86 |
| 2025-09-12 | -15.81 |
| 2025-09-11 | -15.81 |
| 2025-09-10 | -15.79 |
| 2025-09-09 | -15.79 |
| 2025-09-08 | -15.81 |
| 2025-09-05 | -15.79 |
| 2025-09-04 | -15.77 |
| 2025-09-03 | -15.79 |
| 2025-09-02 | -15.75 |
| 2025-08-29 | -15.72 |
| 2025-08-28 | -15.70 |
| 2025-08-27 | -15.72 |
| 2025-08-26 | -15.70 |
| 2025-08-25 | -15.66 |
| 2025-08-22 | -15.68 |
| 2025-08-21 | -15.68 |
| 2025-08-20 | -15.66 |
| 2025-08-19 | -15.66 |
| 2025-08-18 | -15.66 |
| 2025-08-15 | -15.66 |
| 2025-08-14 | -15.64 |
| 2025-08-13 | -15.64 |
| 2025-08-12 | -15.64 |
| 2025-08-11 | -15.66 |
| 2025-08-08 | -15.64 |
| 2025-08-07 | -15.66 |
| 2025-08-06 | -15.66 |
| 2025-08-05 | -15.66 |
| 2025-08-04 | -6.17 |
| 2025-08-01 | -6.92 |
| 2025-07-31 | -6.79 |
| 2025-07-30 | -7.49 |
| 2025-07-29 | -7.88 |
| 2025-07-28 | -7.69 |
| 2025-07-25 | -7.44 |
| 2025-07-24 | -7.60 |
| 2025-07-23 | -7.53 |
| 2025-07-22 | -6.66 |
| 2025-07-21 | -6.48 |
| 2025-07-18 | -6.44 |
| 2025-07-17 | -6.46 |
| 2025-07-16 | -6.52 |
| 2025-07-15 | -6.24 |
| 2025-07-14 | -6.55 |
| 2025-07-11 | -6.55 |
| 2025-07-10 | -6.90 |
| 2025-07-09 | -6.72 |
| 2025-07-08 | -6.22 |
| 2025-07-07 | -6.24 |